Pharmacogénomique des anticancéreux : cas du pembrolizumab

Simple item page
dc.contributor.advisorYounes RAHALI
dc.contributor.authorWaogwendé PASGO
dc.date.accessioned2023-09-15T13:41:42Z
dc.date.accessioned2026-01-22T13:33:40Z
dc.date.available2023-09-15T13:41:42Z
dc.date.issued2021
dc.description.collaboratorYounes RAHALI
dc.description.collaboratorAzeddine IBRAHIMI
dc.description.collaboratorNaima EL HAFIDI
dc.description.collaboratorMouna OUADGHIRI
dc.identifier.urihttps://toubkal.imist.ma/handle/123456789/19113
dc.identifier.urihttps://doi.org/10.83129/toubkal-6609
dc.language.isofr
dc.publisherUniversité Mohammed 5 de Rabat, Faculté de Médecine et de Pharmacie, Rabatfr_FR
dc.subjectPharmacogénomiquefr_FR
dc.subjectAnticancéreuxfr_FR
dc.subjectPembrolizumabfr_FR
dc.subjectBiomarqueursfr_FR
dc.subjectOptimisationfr_FR
dc.subject.otherSciences médicales
dc.subject.specificPharmacologie
dc.titlePharmacogénomique des anticancéreux : cas du pembrolizumabfr_FR

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
P0332021.pdf
Size:
5.89 MB
Format:
Adobe Portable Document Format
Download

Collections

Faculté de Médecine et de Pharmacie - Rabat